Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.

J Immunother Cancer · 2018 · PMC6303974 · PMID 30577837

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

a near-significant trendP = .057so close (0.05 < p ≤ 0.1)

The difference of OS benefit across PD-L1 subgroups obtained a near-significant trend ( P = .057).

also in 290 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.